Recent developments at the FDA, including Marty Makary’s May 2026 resignation after roughly a year in the role and Kyle Diamantas’s subsequent service as acting commissioner, have left the selection process fluid ahead of any formal announcement. Traders assign minimal implied probability across listed names such as Sara Brenner, Stephen Hahn, Brett Giroir, and others because no single candidate has secured visible administration backing or Senate confirmation momentum. Factors that could consolidate support include alignment with current HHS priorities on regulatory reform and public health initiatives, prior agency or White House experience, and the timing of an official nomination before year-end. The low odds on “no announcement by December 31” reflect expectations of movement but underscore uncertainty over which contender will emerge.